Creation of a Biocollection of Patients with Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) or High-risk Myelodysplastic Syndrome (MDS) Monitored At the Nantes University Hospital

Launched by NANTES UNIVERSITY HOSPITAL · Nov 6, 2024

Keywords

ClinConnect Summary

The LANA clinical trial is focused on collecting samples from patients with specific blood cancers: Acute Myeloid Leukemia (AML), Acute Lymphoid Leukemia (ALL), and high-risk Myelodysplastic Syndrome (MDS). The goal is to help researchers at the National Institute of Health and Medical Research (INSERM) better understand these conditions and improve treatment options. If you participate, you will be asked to provide an additional blood or bone marrow sample, beyond what is already required for your medical care, after giving your consent.

To be eligible for this trial, you must be an adult diagnosed with AML, ALL, or MDS, and you need to sign a consent form. However, minors and those under guardianship cannot participate. This trial is not yet recruiting participants, so if you're interested, keep an eye out for updates. Your involvement could contribute to important research that may help many people affected by these serious conditions in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient of legal age affected by AML, ALL or MDS regardless of the time of treatment
• • Patient who has signed the consent form.
• • Patient affiliated with a social security system.
• Exclusion Criteria:
• • Minor patients.
• • Adults under guardianship.
• • Protected persons